



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kocken et. al.

Serial No.: 10/615,615

Filed: July 8, 2003

For: EFFICIENT EXPRESSION OF
PLASMODIUM APICAL MEMBRANE
ANTIGEN 1 IN YEAST CELLS

Confirmation No.: 8276

Examiner:

Group Art Unit: 1636

Attorney Docket No.: 2183-6041US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

12-15-2003
Date

Betty Vowles
Signature

Betty Vowles
Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as

defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56 (b) exists.

Other Documents

EMBL Database Entry PF83B, Accession number M58546, 1 May 1991.

KOCKEN et al., High-Level Expression of Plasmodium vivax Apical Membrane Antigen 1 (AMA-1) in Pichia pastoris: Strong Immunogenicity in Macaca mulatta Immunized with P. vivax AMA-1 and Adjuvant SBAS2, Infection and Immunity, Jan. 1999, pp. 43-49, Vol. 67, No. 1.

KOCKEN et al., Rapid Screening and Mapping of Conformational Epitopes Expressed in the Secretion Expression System Pichia pastoris, Analytical Biochemistry, 1996, pp. 111-112.

NARUM et al., Ion-exchange-immunoaffinity purification of a recombinant baculovirus Plasmodium falciparum apical membrane antigen, PF83/AMA-1, Journal of Chromatography, 1993, pp. 357-63, Vol. 657, Amsterdam.

THOMAS et al., Analysis of variation in PF83, an erythrocytic merozoite vaccine candidate antigen of Plasmodium falciparum, Molecular and Biochemical Parasitology, 1990, pp. 285-288, Vol. 42.


WITHERS-MARTINEZ et al., PCR-based gene synthesis as an efficient approach for expression of the A + T-rich malaria genome, Protein Engineering, 1999, pp. 1113-20, Vol. 12, No. 12.

PCT International Preliminary Examination Report, PCT/NL01/00934, dated November 1, 2002, 3 pages.

Serial No.: 10/615,615

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Allen C. Turner', with a long horizontal flourish extending to the right.

Allen C. Turner
Registration No. 33,041
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: December 15, 2003
ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08
Copy of documents cited

Document in ProLaw



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/615,615
Filing Date	July 8, 2003
First Named Inventor	Kocken et. al.
Group Art Unit	1636
Examiner Name	To be assigned
Attorney Docket Number	2183-60411US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		EMBL Database Entry PFPF83B, Accession number M58546, 1 May 1991.	
		KOCKEN et al., High-Level Expression of Plasmodium vivax Apical Membrane Antigen 1 (AMA-1) in Pichia pastoris: Strong Immunogenicity in Macaca mulatta Immunized with P. vivax AMA-1 and Adjuvant SBAS2, Infection and Immunity, Jan. 1999, pp. 43-49, Vol. 67, No. 1.	
		KOCKEN et al., Rapid Screening and Mapping of Conformational Epitopes Expressed in the Secretion Expression System Pichia pastoris, Analytical Biochemistry, 1996, pp. 111-112.	
		NARUM et al., Ion-exchange-immunoaffinity purification of a recombinant baculovirus Plasmodium falciparum apical membrane antigen, PF83/AMA-1, Journal of Chromatography, 1993, pp. 357-63, Vol. 657, Amsterdam.	
		THOMAS et al., Analysis of variation in PF83, an erythrocytic merozoite vaccine candidate antigen of Plasmodium falciparum, Molecular and Biochemical Parasitology, 1990, pp. 285-288, Vol. 42.	
		WITHERS-MARTINEZ et al., PCR-based gene synthesis as an efficient approach for expression of the A + T-rich malaria genome, Protein Engineering, 1999, pp. 1113-20, Vol. 12, No. 12.	
		PCT International Preliminary Examination Report, PCT/NL01/00934, dated November 1, 2002, 3 pages.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.